Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose streptozotocin

Journal of Ethnopharmacology

Volumn 169, Issue , 2015, Pages 269-274

  Manaer, Tabusi ^a,b   Yu, Lan ^a   Zhang, Yi ^a   Xiao, Xue Jun ^a   Nabi, Xin Hua ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b Xinjiang Uyghur Autonomous Region Institute for Food and Drug Control   (China)

Author keywords

Fermentedcamelmilk; GLP 1; Probiotics; Shubat; Type 2diabeticrats

Indexed keywords

C PEPTIDE; CREATININE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBIOTIC AGENT; SHUBAT; SITAGLIPTIN; STREPTOZOCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CARBOHYDRATE DIET; CHOLESTEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CANDIDA; CANDIDA ETHANOLICA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DRUG MEGADOSE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPOLIPEMIA; KLUYVEROMYCES MARXIANUS; LABORATORY TEST; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOBACILLUS HARBINENSIS; LACTOBACILLUS HELVETICUS; LACTOBACILLUS HILGARDII; LACTOBACILLUS MUCOSAE; LACTOBACILLUS PAR; LACTOBACILLUS PARACASEI; LACTOBACILLUS PENTOSUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOCOCCUS LACTIS; LIPID DIET; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PICHIA KUDRIAVZEVII; PICHIA MEMBRANIFACIENS; RAT; RENAL PROTECTION; TISSUE SECTION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ADVERSE EFFECTS; ANIMAL; BLOOD; CARBOHYDRATE DIET; CHEMICALLY INDUCED; DAIRY PRODUCT; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; HYPERTROPHY; KIDNEY; PANCREAS; PATHOLOGY;

RATTUS;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; CHOLESTEROL; CULTURED MILK PRODUCTS; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DIETARY CARBOHYDRATES; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HYPERTROPHY; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; PANCREAS; PROBIOTICS; RATS; SITAGLIPTIN PHOSPHATE; STREPTOZOCIN;

EID: 84929207705     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.04.032     Document Type: Article

References (40)

1. R.P. Agrawal, P. Tantia, S. Jain, R. Agrawal, and V. Agrawal Camel milk: a possible boon for type 1 diabetic patients Cell. Mol. Biol. (Noisy-le-Grand, Fr.) 59 1 2012 99 107
2. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 34 2011 S62 S69
3. W. Baheti, H Liu, and N. Xin-Hua Evaluation of immunomodulatory effects of bioactive peptides derived from fermented camel milk on splenocytes proliferation China Dairy Ind. 42 4 2014 15 17
4. P.D. Cani, E. Lecourt, E.M. Dewulf, F.M. Sohet, B.D. Pachikian, D. Naslain, and N.M. Delzenne Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal Am. J. Clin. Nutr. 90 5 2009 1236 1243
5. M.I. Constantino, L. Molyneaux, F. Limacher-Gisler, A. Al-Saeed, C. Luo, T. Wu, and J. Wong Long-term complications and mortality in young-onset diabetes type 2 diabetes is more hazardous and lethal than type 1 diabetes Diabetes Care 36 12 2013 3863 3869
6. M.J. Dailey, and T.H. Moran Glucagon-like peptide 1 and appetite Trends Endocrinol. Metab. 24 2 2013 85 91
7. N.M. Delzenne, A.M. Neyrinck, F. Bäckhed, and P.D. Cani Targeting gut microbiota in obesity: effects of prebiotics and probiotics Nat. Rev. Endocrinol. 7 11 2011 639 646
8. M.Y. Donath, and S.E. Shoelson Type 2 diabetes as an inflammatory disease Nat. Rev. Immunol. 11 2 2011 98 107
9. H. Ellingsgaard, I. Hauselmann, B. Schuler, A.M. Habib, L.L. Baggio, D.T. Meier, and M.Y. Donath Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells Nat. Med. 17 11 2011 1481 1489
10. Z. Fehervari Bridging inflammation in obesity Nat. Immunol. 13 10 2012 946
11. G.S. Getz, G.D. Wool, and C.A. Reardon HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders Curr. Pharm. Des. 16 28 2010 3173
12. A. Guilherme, J.V. Virbasius, V. Puri, and M.P. Czech Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes Nat. Rev. Mol. Cell Biol. 9 5 2008 367 377
13. K. Guliziya, and N. Xin-Hua Anti-inflammatory effects and mechanism of Xinjiang Kazakh traditional fermented camel milk China Dairy Ind. 35 9 2007 8 10
14. L. Juillerat-Jeanneret Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? J. Med. Chem. 57 6 2013 2197 2212
15. F. Kahles, C. Meyer, J. Möllmann, S. Diebold, H.M. Findeisen, C. Lebherz, and M. Lehrke GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering Diabetes 63 10 2014 3221 3229
16. A.A. Korish The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines Horm. Metab. Res. 46 6 2014 404 411
17. I.M. Lacroix, and E.C. Li-Chan Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins Peptides 54 2014 39 48
18. A. Latipa, T. Xue, and N. Xin-Hua Molecular biological identification of one lactic acid bacteria in Xinjiang traditional fermented camel milk J. Xinjiang Med. Univ. 34 2 2014 155 159
19. N. Li, H. Wang, Z. Yan, X. Yao, J. Hong, and L. Zhou Ethnic disparities in the clustering of risk factors for cardiovascular disease among the Kazakh, Uygur, Mongolian and Han populations of Xinjiang: a cross-sectional study BMC Public Health 12 1 2012 499
20. L.C. Luna Manual of Histological Screening Methods of Armed Forces Institute of Pathology 1960 McGraw Hill Book Co. New York
21. P. Mirmiran, Z. Bahadoran, and F. Azizi Functional foods-based diet as a novel dietary approach for management of type 2 diabetes and its complications: a review World J. Diabetes 5 3 2014 267 281
22. P. Nadkarni, O.G. Chepurny, and G.G. Holz Regulation of glucose homeostasis by GLP-1 Prog. Mol. Biol. Transl. Sci. 121 2014 23
23. A.B. Nongonierma, and R.J. FitzGerald Dipeptidyl peptidase IV inhibitory and antioxidative properties of milk protein-derived dipeptides and hydrolysates Peptides 39 2013 157 163
24. J.E. Shaw, R.A. Sicree, and P.Z. Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Res. Clin. Pract. 87 1 2010 4 14
25. S. Shigemori, K. Oshiro, P. Wang, Y. Yamamoto, Y. Wang, T. Sato, and T. Shimosato Generation of dipeptidyl peptidase-IV-inhibiting peptides from β-lactoglobulin secreted by Lactococcus lactis BioMed Res. Int. 2014 2014 393598 10.1155/2014/393598
26. S.T. Silveira, D. Martínez-Maqueda, I. Recio, and B. Hernández-Ledesma Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin Food Chem. 141 2 2013 1072 1077
27. S. Skovsø Modeling type 2 diabetes in rats using high fat diet and streptozotocin J. Diabetes Investig. 5 4 2014 349 358
28. R. Spiller Probiotics: an ideal anti-inflammatory treatment for IBS? Gastroenterology 128 3 2005 783 785
29. K. Srinivasan, B. Viswanad, L. Asrat, C.L. Kaul, and P. Ramarao Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening Pharmacol. Res. 52 4 2005 313 320
30. A.G. Tabák, M. Jokela, T.N. Akbaraly, E.J. Brunner, M. Kivimäki, and D.R. Witte Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study Lancet 373 9682 2009 2215 2221
31. A.J. Tremblay, B. Lamarche, I. Kelly, A. Charest, M.C. Lépine, A. Droit, and P. Couture Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes Diabetes Obes. Metab. 16 12 2014 1223 1229
32. G. Tulipano, V. Sibilia, A.M. Caroli, and D. Cocchi Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors Peptides 32 4 2011 835 838
33. L. Wang, Y. Tao, Z. Xie, X. Ran, M. Zhang, Y. Wang, and X. Mao Prevalence of metabolic syndrome, insulin resistance, impaired fasting blood glucose, and dyslipidemia in Uygur and Kazak populations J. Clin. Hypertens. 12 9 2010 741 745
34. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King Global prevalence of diabetes estimates for the year 2000 and projections for 2030 Diabetes Care 27 5 2004 1047 1053
35. Y. Xu, L. Wang, J. He, Y. Bi, M. Li, T. Wang, and G. Ning Prevalence and control of diabetes in Chinese adults JAMA 310 9 2013 948 959
36. Z. Xu, J. Ju, K. Wang, C. Gu, and Y. Feng Evaluation of hypoglycemic activity of total lignans from Fructus Arctii in the spontaneously diabetic Goto-Kakizaki rats J. Ethnopharmacol. 151 1 2014 548 555
37. H. Yadav, S. Jain, and P.R. Sinha Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats Nutrition 23 1 2007 62 68
38. W. Yan, X. Yang, Y. Zheng, D. Ge, Y. Zhang, Z. Shan, and R. Wang The metabolic syndrome in Uygur and Kazak populations Diabetes Care 28 10 2005 2554 2555
39. W.L. Yan, X.S. Li, Q. Wang, Y.D. Huang, W.G. Zhang, X.H. Zhai, and J.H. Lee Overweight, high blood pressure and impaired fasting glucose in Uyghur, Han, and Kazakh Chinese children and adolescents Ethn. Health 2014 1 11 (Epub ahead of print)
40. H.W. Zhang, S. Jiang, and Y.C. Xu A cross-sectional study on serum uric acid level and the distribution of metabolic syndrome among Uigur, Han and Kazak prediabetic groups in Xinjiang Zhonghua liu xing bing xue za zhi 34 10 2013 958 960